Clinical Trial

Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy. It will also learn about the safety of NRICM102. The main questions it aims to answer are: 1. Does NRICM102 help participants reach clinical stability faster compared to placebo? 2. What medical problems do participants have when taking NRICM102? Researchers will compare NRICM102 to a placebo (a look-alike substance that contains no drug) to see if NRICM102 works as an add-on treatment for community-acquired pneumonia. Participants will: 1. Take NRICM102 or a placebo (2 sachets, 3 times daily) in addition to standard intravenous antibiotic treatment for 7 days 2. Be hospitalized and visited by the study team on Day 1, Day 4, and Day 8 for vital sign monitoring, symptom assessments, laboratory tests, and chest X-ray examinations 3. Be contacted by telephone on Day 30 to check if they were readmitted to the hospital after discharge
Trial Details
NCT Number NCT07583992
Lead Sponsor National Research Institute of Chinese Medicine, Ministry of Health and Welfare
Collaborators: StatPlus,Inc.
Conditions Mild to Moderate, Community-Acquired Pneumonia (CAP), Antibiotic Therapy, Intravenous, Hospitalisation
Enrollment 150 participants
Start Date 2026-06
Primary Completion 2027-03 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-13